Receptor-mediated targeting of spray-dried lipid particles coformulated with immunoglobulin and loaded with a prototype vaccine

被引:27
作者
Bot, AI
Smith, DJ
Bot, S
Dellamary, L
Tarara, TE
Harders, S
Phillips, W
Weers, JG
Woods, CM
机构
[1] Alliance Pharmaceut Corp, Dept Biol Res, San Diego, CA 92121 USA
[2] Alliance Pharmaceut Corp, Dept Pharmaceut Res, San Diego, CA 92121 USA
关键词
microparticles; ligand; cell targeting; vaccines; surfactant-lipid;
D O I
10.1023/A:1010988311640
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. Spray-dried lipid-based microparticles (SDLM) serve as a platform for delivery of a wide variety of compounds including peptides, proteins, and vaccines to the respiratory mucosa. In the present study, we assessed the impact of IgC-mediated targeting to phagocytic cells of inactivated influenza virus formulated in SDLM, on subsequent immune responses. Methods. SDLM were produced containing inactivated influenza virus strain A/WSN/32/H1N1 (WSN), with or without IgG. Using phagocytic antigen presenting cells (APC) and a T cell hybridoma (TcH) line specific for a dominant influenza virus epitope, we compared the in vitro responses elicited by ligand-formulated (SDLM-IgG-WSN) and non-ligand particles (SDLM-WSN). The effect of including the IgG ligand in the formulation was further characterized by measuring the immune responses of rodents vaccinated with SDLM. Results. SDLM-IgG-WSN were internalized in an Pc receptor (FcR)-dependent manner by phagocytic APC that were then able to effectively present a dominant, class II-restricted epitope to specific T cells. While SDLM-WSN elicited a lower response than administration of plain inactivated virus in saline, the level of the T cell response was restored both in vitro and in vivo by incorporating the APC FcR ligand, IgG, in the SDLM. Conclusions. Incorporation of FcR ligand (IgG) in SDLM restored the limited ability of formulated virus to elicit T-cell immunity, by receptor-mediated targeting to phagocytes.
引用
收藏
页码:971 / 979
页数:9
相关论文
共 32 条
[21]   PROTECTION OF MICE FROM BORDETELLA-PERTUSSIS RESPIRATORY-INFECTION USING MICROENCAPSULATED PERTUSSIS FIMBRIAE [J].
JONES, DH ;
MCBRIDE, BW ;
JEFFERY, H ;
OHAGAN, DT ;
ROBINSON, A ;
FARRAR, GH .
VACCINE, 1995, 13 (07) :675-681
[22]   Virosomes: evolution of the liposome as a targeted drug delivery system [J].
Kaneda, Y .
ADVANCED DRUG DELIVERY REVIEWS, 2000, 43 (2-3) :197-205
[23]   ISOLATION OF APOPROTEINS FROM CANINE SURFACE-ACTIVE MATERIAL [J].
KING, RJ ;
KLASS, DJ ;
GIKAS, EG ;
CLEMENTS, JA .
AMERICAN JOURNAL OF PHYSIOLOGY, 1973, 224 (04) :788-795
[24]   PROTECTION AGAINST VAGINAL SIV TRANSMISSION WITH MICROENCAPSULATED VACCINE [J].
MARX, PA ;
COMPANS, RW ;
GETTIE, A ;
STAAS, JK ;
GILLEY, RM ;
MULLIGAN, MJ ;
YAMSHCHIKOV, GV ;
CHEN, DX ;
ELDRIDGE, JH .
SCIENCE, 1993, 260 (5112) :1323-1327
[25]   Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8(+) cytotoxic T lymphocytes and CD4(+) Th1 cells [J].
Moore, A ;
McGuirk, P ;
Adams, S ;
Jones, WC ;
McGee, JP ;
OHagan, DT ;
Mills, KHG .
VACCINE, 1995, 13 (18) :1741-1749
[26]  
REED L. J., 1938, AMER JOUR HYG, V27, P493
[27]   ADJUVANTICITY AND PROTECTIVE IMMUNITY ELICITED BY BORDETELLA-PERTUSSIS ANTIGENS ENCAPSULATED IN POLY(DL-LACTIDE-CO-GLYCOLIDE) MICROSPHERES [J].
SHAHIN, R ;
LEEF, M ;
ELDRIDGE, J ;
HUDSON, M ;
GILLEY, R .
INFECTION AND IMMUNITY, 1995, 63 (04) :1195-1200
[28]   ENTERAL IMMUNIZATION AND CHALLENGE OF VOLUNTEERS GIVEN ENTEROTOXIGENIC ESCHERICHIA-COLI CFA/II ENCAPSULATED IN BIODEGRADABLE MICROSPHERES [J].
TACKET, CO ;
REID, RH ;
BOEDEKER, EC ;
LOSONSKY, G ;
NATARO, JP ;
BHAGAT, H ;
EDELMAN, R .
VACCINE, 1994, 12 (14) :1270-1274
[29]  
THEPEN T, 1993, ADV EXP MED BIOL, V329, P305
[30]  
Thomasin C, 1996, EUR J PHARM BIOPHARM, V42, P16